跳至主要内容
临床试验/NCT01256801
NCT01256801已完成不适用

Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy

Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2010年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
36
试验地点
1
主要终点
immunotherapy response

研究概览

简要总结

The investigators want to develop a gene expression profile for the prediction of immunotherapy response of patients with metastatic breast cancer presenting malignant pleural effusion.

详细描述

  1. The patiets with malignant pleural effusion are randomizned to be treated with cytokins(inteleukin 2) or dendritic cells(DC) plus cytokine induced killer cells(CIK) locally.
  2. Malignant pleural effusion from metastatic breast cancer patient is obtained through thoracentesis and is centrifugalized to enrich cancer cells before the therapy.
  3. The enriched cancer cells are flash frozen and stored at -80℃ until processing.
  4. The gene expression in pleural effusion is detected by microarray to screen gene markers that are differently expressed between groups .
  5. Statistical analysis is performed using unsupervised hierarchical cluster.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients should be histologically confirmed with metastatic breast cancer and malignant pleural effusion
  • an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  • At least one measurable lesion;
  • Normal cardiac, hepatic, renal and bone marrow functions;
  • Life expectancy ≥3 months;
  • Discontinuity of previous chemotherapy for a minimum of 4 weeks.
  • Not receive chemotherapy in pleural cavity

排除标准

  • previous history of other malignancies;
  • previous surgery history on the needle biopsy organ;
  • Serious or uncontrolled concurrent medical illness.

结局指标

主要结局

immunotherapy response

时间窗: 1 month

Response of malignant pleural effusion to immunotherapy is evaluated with WHO guidelines

次要结局

  • immunological status(1 month)

研究者

发起方
Peking University Cancer Hospital & Institute
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jun Ren

Director

Peking University Cancer Hospital & Institute

研究点 (1)

Loading locations...

相似试验